We are recruiting participants for our new CHARM study, titled “cfDNA in Hereditary And High-Risk Malignancies (CHARM) 2: Evaluating the Performance of a cfDNA Blood Test for Early Cancer Detection”
We are currently recruiting participants at the University Health Network in Toronto who fulfill the following criteria:
1. Individuals with a pathogenic/likely pathogenic variant in one of the following genes:
- BRCA1, BRCA2, PALB2 (Hereditary Breast and Ovarian Cancer)
- CDH1 (Hereditary Diffuse Gastric Cancer)
- MLH1, MSH2, MSH6, PMS2, EPCAM (Lynch Syndrome)
- NF1 (Neurofibromatosis Type 1)
- TP53 (Li-Fraumeni Syndrome)
2. Individuals with and without a personal history of cancer are eligible. However, at the time of study enrollment, individuals must be cancer free for at least 3 years.
Information about the CHARM2 study can be found here.
If you fulfill the above criteria and are interesting in participating in this study, please contact us.